Chemotherapy following Surgery for Head and Neck Cancer
| Autor: | Steven Leibel, Jeannie J. Kinzie, Muhyi Al-Sarraf, Lawrence W. Davis, John R. Jacobs, JoAnn Stetz, Thomas F. Pajak, George E. Laramore |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Nausea medicine.medical_treatment Radiotherapy High-Energy Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Multicenter Studies as Topic Combined Modality Therapy Chemotherapy business.industry Standard treatment Head and neck cancer Cancer Middle Aged medicine.disease Surgery Radiation therapy Head and Neck Neoplasms Carcinoma Squamous Cell Vomiting Female Fluorouracil Cisplatin medicine.symptom business |
| Zdroj: | American Journal of Clinical Oncology. 12:185-189 |
| ISSN: | 0277-3732 |
| Popis: | The feasibility of chemotherapy of three courses of cis-platin and 120-h 5-fluorouracil (5-FU) infusion after definitive surgery, followed by standard radiotherapy, in patients with resectable locally advanced head and neck cancer was carried out in Radiation Therapy Oncology Group (RTOG). Seventy-nine percent of the patients had stage IV cancer, 65% of the tumors were moderately differentiated, and primary sites were 38% oropharynx and 28% larynx. Toxicity to chemotherapy was acceptable, with no life-threatening side effects. Nausea and vomiting were the most common side effects (78%) and were severe in 26%; 30% of patients experienced had leukopenia, 22% had anemia, 13% had thrombocytopenia, and 9% had renal impairment--all of which were mild and reversible. In six patients, chemotherapy was not given for medical conditions or because of patient refusal. Of 23 patients started on cis-platin and 5-FU postsurgery, 18 (78%) completed all three courses. Ninety-six percent of the patients finished adequate radiotherapy according to the protocol. With minimum follow-up of 24 months, 62% of the patients were alive. Of the expired patients, 5 died from other causes, without evidence of recurrence at the time of their death. It is our conclusion that chemotherapy with cis-platin and 5-FU infusion following definitive surgery is feasible on the group level, and a Phase III trial comparing this combined modality therapy to standard treatment of surgery and post-operative radiotherapy is underway by the Head and Neck Cancer Intergroup. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|